| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 22 |
| 1 | OXALIPLATIN | 20 |
| 2 | CAPECITABINE | 16 |
| 3 | FLUOROURACIL | 13 |
| 4 | FLUOROURACIL CREAM, 0.5% | 13 |
| 5 | PANITUMUMAB | 7 |
| 6 | REGORAFENIB | 6 |
| 7 | CETUXIMAB | 5 |
| 8 | ADALIMUMAB | 4 |
| 9 | HYDROCHLOROTHIAZIDE | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LANOLIN, PETROLATUM | 1 | 0.0040 |
| 1 | LANOLIN AND PETROLATUM | 1 | 0.0038 |
| 2 | LIDOCAINE AND PRILOCAINE | 1 | 0.0007 |
| 3 | WHITE PETROLATUM | 1 | 0.0007 |
| 4 | FLURBIPROFEN | 1 | 0.0007 |
| 5 | LEVOLEUCOVORIN INJECTION | 2 | 0.0007 |
| 6 | CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE | 2 | 0.0006 |
| 7 | LEVOLEUCOVORIN | 2 | 0.0005 |
| 8 | REGORAFENIB | 6 | 0.0005 |
| 9 | FRUQUINTINIB | 2 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 12 | 0.0003 |
| 1 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 2 | 0.0002 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 25 | 0.0001 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 25 | 0.0001 |
| 4 | Platinum-based Drug [EPC] | 20 | 0.0001 |
| 5 | RNA Synthetase Inhibitor Antibacterial [EPC] | 1 | 0.0001 |
| 6 | Vasopressin V2 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 7 | Phenothiazine [EPC] | 2 | 0.0001 |
| 8 | Androgen Receptor Inhibitor [EPC] | 2 | 0.0000 |
| 9 | Cholinergic Muscarinic Antagonist [EPC] | 1 | 0.0000 |